Zydus Lifesciences informs about press release

06 Nov 2025 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated November 6, 2025, titled ‘Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of betathalassemia’.

The above information is a part of company’s filings submitted to BSE.  

Zydus Lifesciences Share Price

902.15 10.60 (1.19%)
09-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.35
Dr. Reddys Lab 1212.35
Cipla 1224.25
Zydus Lifesciences 902.15
Lupin 2296.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×